Non Small Cell Lung Cancer Stage Iiib clinical trials

Explore recruiting non small cell lung cancer stage iiib clinical trials.

Recruiting non small cell lung cancer stage iiib studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Small Cell Lung Cancer Stage Iiib trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1 positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Greece, France, Austria, Romania, Spain, Poland +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

IFCT-2003 ALBATROS A phase II single-group assignment, multicenter study of efficacy and safety of lorlatinib monotherapy after failure of first-line tyrosine kinase inhibitor in patients with advanced ROS1-positive non-small cell lung cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).

France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung cancer treated with definitive chemo-radiotherapy (MP-LALC- Maintainance Pembrolizumab in Locally Advanced Lung Cancer).

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Non Small Cell Lung Cancer Stage Iiib trials by city

Non Small Cell Lung Cancer Stage Iiib in Toronto Non Small Cell Lung Cancer Stage Iiib in Vancouver Non Small Cell Lung Cancer Stage Iiib in Montreal Non Small Cell Lung Cancer Stage Iiib in Calgary Non Small Cell Lung Cancer Stage Iiib in Edmonton Non Small Cell Lung Cancer Stage Iiib in Ottawa Non Small Cell Lung Cancer Stage Iiib in Winnipeg Non Small Cell Lung Cancer Stage Iiib in Quebec City Non Small Cell Lung Cancer Stage Iiib in Hamilton Non Small Cell Lung Cancer Stage Iiib in Kitchener Non Small Cell Lung Cancer Stage Iiib in London Non Small Cell Lung Cancer Stage Iiib in Halifax Non Small Cell Lung Cancer Stage Iiib in New York Non Small Cell Lung Cancer Stage Iiib in Los Angeles Non Small Cell Lung Cancer Stage Iiib in Chicago Non Small Cell Lung Cancer Stage Iiib in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease